Lakewood-Amedex, Inc. to Present at 2018 BIO CEO & Investor Conference

Thursday, February 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SARASOTA, Fla., Feb. 8, 2018 /PRNewswire/ -- Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals,

today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.

Steve Parkinson, President

and CEO of Lakewood-Amedex, plans to present data on the Company's lead therapeutic candidate, Nu-3, a topically applied antimicrobial which recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU). The presentation will also highlight the Company's second drug candidate, Nu-8, which Lakewood-Amedex anticipates advancing into preclinical IND-enabling studies following positive pre-IND written communications with the FDA. Nu-8 will be developed for the treatment of complicated urinary tract infections (cUTI) that are currently treated with systemic orally delivered antibiotics.

Lakewood-Amedex Presentation Details:Date: Tuesday, February 13, 2018 Time: 9:45 AM (Eastern Time)Location: New York Marriott Marquis, Gilbert Room

An audio webcast will be accessible for 90 days following the presentation via the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2018/58208329358.cfm 

About Lakewood-Amedex, Inc.Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).

Contacts:Tiberend Strategic Advisors, Inc.Jonathon Brzezinski, Ph.D. (investors)jbrzezinski@tiberend.com (212) 375-2681

Tiberend Strategic Advisors, Inc.David Schemelia (media)dschemelia@tiberend.com (212) 375-2686

Cision View original content:http://www.prnewswire.com/news-releases/lakewood-amedex-inc-to-present-at-2018-bio-ceo--investor-conference-300595543.html

SOURCE Lakewood-Amedex, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store